Literature DB >> 12100228

CYP2D6 deficiency, a factor in ecstasy related deaths?

T C Gilhooly, A K Daly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12100228      PMCID： PMC1874389          DOI： 10.1046/j.1365-2125.2002.01574.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.

Authors:  K Kreth; K Kovar; M Schwab; U M Zanger
Journal:  Biochem Pharmacol       Date:  2000-06-15       Impact factor: 5.858

2.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.

Authors:  C A Smith; A C Gough; P N Leigh; B A Summers; A E Harding; D M Maraganore; S G Sturman; A H Schapira; A C Williams; D M Maranganore
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

3.  Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

Authors:  A K Daly; M Armstrong; S C Monkman; M E Idle; J R Idle
Journal:  Pharmacogenetics       Date:  1991-10

4.  Pathology of deaths associated with "ecstasy" and "eve" misuse.

Authors:  C M Milroy; J C Clark; A R Forrest
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

5.  Places and patterns of drug use in the Scottish dance scene.

Authors:  A J Forsyth
Journal:  Addiction       Date:  1996-04       Impact factor: 6.526

6.  CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.

Authors:  J B Leathart; S J London; A Steward; J D Adams; J R Idle; A K Daly
Journal:  Pharmacogenetics       Date:  1998-12

7.  Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.

Authors:  C Beyeler; M Armstrong; H A Bird; J R Idle; A K Daly
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

8.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).

Authors:  G T Tucker; M S Lennard; S W Ellis; H F Woods; A K Cho; L Y Lin; A Hiratsuka; D A Schmitz; T Y Chu
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858
  8 in total
  7 in total

1.  Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.

Authors:  Samanta Yubero-Lahoz; Ricardo Pardo; Magí Farré; Brian O'Mahony; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Marcel Lí Carbó; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

Review 2.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

Review 3.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

Review 4.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

Authors:  Rafael de la Torre; Samanta Yubero-Lahoz; Ricardo Pardo-Lozano; Magí Farré
Journal:  Front Genet       Date:  2012-11-12       Impact factor: 4.599

6.  Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Authors:  Mireia Segura; Magí Farré; Simona Pichini; Ana M Peiró; Pere N Roset; Ariel Ramírez; Jordi Ortuño; Roberta Pacifici; Piergiorgio Zuccaro; Jordi Segura; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.

Authors:  Yasmin Schmid; Patrick Vizeli; Cédric M Hysek; Katharina Prestin; Henriette E Meyer Zu Schwabedissen; Matthias E Liechti
Journal:  Pharmacogenet Genomics       Date:  2016-08       Impact factor: 2.089
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.